A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD

This publication has 17 references indexed in Scilit:

• Clinical epidemiology of cardiovascular disease in chronic renal disease
  American Journal of Kidney Diseases, 1998
• Prevention of coronary heart disease in clinical practice Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention
  European Heart Journal, 1998
• An Overview of the Clinical Safety Profile of Atorvastatin (Lipitor), a New HMG-CoA Reductase Inhibitor
  Archives of internal medicine (1960), 1998
• Comparative Dose Efficacy Study of Atorvastatin Versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in Patients With Hypercholesterolemia (The CURVES Study) fn1fn1This study was supported by Parke-Davis, Division of Warner Lambert Company, Morris Plains, New Jersey. Manuscript received August 20, 1997; revised manuscript received and accepted November 24, 1997.
  The American Journal of Cardiology, 1998
• Renal Dysfunction Does Not Alter the Pharmacokinetics or LDL‐Cholesterol Reduction of Atorvastatin
  The Journal of Clinical Pharmacology, 1997
• A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients witb hypercholesterolemia
  The American Journal of Cardiology, 1997
• Comparison of One-Year Efficacy and Safety of Atorvastatin Versus Lovastatin in Primary Hypercholesterolemia
  The American Journal of Cardiology, 1997
• Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia
  Atherosclerosis, 1997
• Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase Inhibitor
  Arteriosclerosis, Thrombosis, and Vascular Biology, 1995
• Prevention of coronary heart disease in clinical practice
  European Heart Journal, 1994